AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00488644
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mcg by mouth (PO) Daily for 8 Weeks
Trial: NCT00488644
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mcg PO Daily for 8 Weeks
Trial: NCT03279757
Drug: AHES 5 minutes
RxNorm normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Trial: NCT03279757
Drug: AHES 15 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Trial: NCT03279757
Drug: AHES 25 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Trial: NCT03279757
Drug: LTC 5 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Trial: NCT03279757
Drug: LTC 15 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Trial: NCT04002115
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given once a day for 2 days after the transplant infusion.
Trial: NCT03546491
Drug: Preventive Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% Stannous Fluoride
Trial: NCT03546491
Drug: Marketed Control
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.243% Sodium Fluoride
Trial: NCT04091789
Drug: Pure Femme Tablets
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
Trial: NCT00994461
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 100mg tablet twice a day with meal for 2 weeks
Trial: NCT00994461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet three times a day with meal for 2 weeks
Trial: NCT02941692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Oxytocin
Trial: NCT03271281
Drug: One injection of 68Ga-NODAGA-E[c(RGDyK)]2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
Trial: NCT04195204
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators administrated intravenously saline solution as a placebo
Trial: NCT03066648
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
Trial: NCT01710202
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
Trial: NCT00144521
Drug: MRA placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg/kg/4week(i.v.) for 24 weeks
Trial: NCT00144521
Drug: MTX placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg/week(p.o.) for 24 weeks
Trial: NCT04443946
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
Trial: NCT01056237
Drug: Multi-target therapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
Trial: NCT01056237
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.0-2.0mg/kg/d
Trial: NCT02336568
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
Trial: NCT00097825
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02256124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02913183
Drug: young Fresh Frozen Plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood plasma from healthy male donors aged 18-30 years old.
Trial: NCT02913183
Drug: old Fresh Frozen Plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood plasma from healthy male donors aged 40-55 years old.
Trial: NCT01965366
Drug: 0.5 mg DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
Trial: NCT00928291
Drug: antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic therapy use
Trial: NCT02295826
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
Trial: NCT01172925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaler
Trial: NCT00022698
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02134015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion every 3 weeks
Trial: NCT03685253
Drug: Niagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
Trial: NCT03685253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
Trial: NCT04143854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection; normal saline
Trial: NCT02705300
Drug: Calcium folinate 200 mg/m2 iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Max. 6 months
Trial: NCT02705300
Drug: 5-fluorouracil 3200 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Max. 6 months
Trial: NCT02705300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Max. 2 years or at the discretion of the investigator
Trial: NCT00894439
Drug: BLI-489
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05125796
Drug: Dexketoprofen Trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline
Trial: NCT05125796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL intravenous normal saline infusion+ placebo topical pomade application
Trial: NCT03032042
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03032042
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole+Azithromycin
Trial: NCT02024607
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02024607
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02024607
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03756623
Drug: Probiotics powder
RxNorm normalized name: Nutricia Neocate Syneo Infant Prebiotics + Probiotics Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5g of Probiotics powder administered three times a day orally before meal
Trial: NCT00502385
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00468481
Drug: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
Trial: NCT00468481
Drug: Drospirenone/Ethinylestradiol (Yaz)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.020 mg ethinylestradiol with 3.0 mg drospirenone
Trial: NCT00415818
Drug: 1st line Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02992236
Drug: VAS203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of NO-Synthase inhibitor VAS203
Trial: NCT01234870
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00044070
Drug: YM872 (zonampanel)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04108468
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate
Trial: NCT00734162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF placebo tablet once daily
Trial: NCT03298958
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will be randomized to one of the 2 arms
Trial: NCT03097341
Drug: xisomab 3G3- Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
Trial: NCT03097341
Drug: xisomab 3G3-Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
Trial: NCT03097341
Drug: xisomab 3G3-Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
Trial: NCT03097341
Drug: xisomab 3G3- Dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
Trial: NCT01568034
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 9-1067 - 25 mg single-dose
Trial: NCT01568034
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 9-1067 - 50 mg single-dose
Trial: NCT01568034
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 9-1067 - 100 mg single-dose
Trial: NCT01568034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose
Trial: NCT01568034
Drug: Levodopa/Benzerazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 100 mg Benzerazide 25 mg
Trial: NCT02393950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
Trial: NCT01262287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules in same number as active drug, daily for 8-week treatment period
Trial: NCT04527289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be managed with placebo as add on to the standard regimen.
Trial: NCT03805568
Drug: remifentanil infusion group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil as anaesthetic adjuvant
Trial: NCT00918411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01146093
Drug: Pravastatin Sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin Sodium Tablets 80 mg
Trial: NCT02657122
Drug: Placebo for SAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
Trial: NCT02657122
Drug: Placebo for MAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
Trial: NCT04506463
Drug: MM-II dose II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection
Trial: NCT04506463
Drug: MM-II dose III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection
Trial: NCT04506463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection
Trial: NCT01475708
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg PO bid, 14 days
Trial: NCT02975388
Drug: RO7079901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
Trial: NCT03205956
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above.
Trial: NCT01232413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01232413
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03005496
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: included in intervention arm
Trial: NCT02763137
Drug: Standard LD/CD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD/CD will be administered at patient's usual dose and frequency during 8 hours interval
Trial: NCT02763137
Drug: Semi continuous intra-oral administration of LD/CD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi continuous intra-oral administration of standard LD/CD at a dose equal to the total dose of standard oral LD/CD that patients would normally consume over 8 hours period.
Trial: NCT00324025
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01017770
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
Trial: NCT00744965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham dose adjustments of the placebo will be made.
Trial: NCT03128138
Drug: SPH3127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SPH3127 Tablet~Drug: Placebo Tablet
Trial: NCT02339532
Drug: FEC100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²
Trial: NCT03934736
Drug: HEPLISAV-B®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine for adults 18 years of age and older, consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).
Trial: NCT04173455
Drug: HZ-A-018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort.
Trial: NCT00026273
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00026273
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00026273
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01998802
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02737930
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02737930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02693002
Drug: Estradiol/Norethindrone acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol/Norethindrone acetate 1mg/0.5 mg
Trial: NCT02693002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive ingredient
Trial: NCT02064816
Drug: Rebif®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
Trial: NCT02064816
Drug: Rebif®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
Trial: NCT01757184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions of matched placebo
Trial: NCT02260336
Drug: Celecoxib Capsule 400 mg daily
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00602836
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
Trial: NCT00865878
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
Trial: NCT02639650
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h\*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
Trial: NCT02639650
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
Trial: NCT01718678
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: it is kind of drug
Trial: NCT01718678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is Placebo
Trial: NCT01135433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00250952
Drug: Botox Cosmetic™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01377922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
Trial: NCT00586820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
Trial: NCT04153760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo p.o. daily
Trial: NCT01157104
Drug: IDX320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX320 400 mg in tablets (8x50 mg) administered orally once daily
Trial: NCT01157104
Drug: IDX184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 100 mg in capsules (2x50 mg) administered orally once daily
Trial: NCT01157104
Drug: IDX184 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 matching placebo in capsules administered orally once daily
Trial: NCT01157104
Drug: IDX320 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX320 matching placebo in tablets administered orally once daily